Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8%

Structure Therapeutics Inc. (NASDAQ:GPCR) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 15th total of 10,160,000 shares. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is presently 13.0 days. Currently, 19.8% of the company’s stock are sold short.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded up $0.08 during trading on Friday, reaching $27.06. The company’s stock had a trading volume of 846,835 shares, compared to its average volume of 770,004. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -36.57 and a beta of -2.78. Structure Therapeutics has a 12 month low of $23.50 and a 12 month high of $62.74. The firm has a 50 day moving average of $30.78 and a 200-day moving average of $36.03.

Institutional Trading of Structure Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Sandia Investment Management LP bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $39,000. GAMMA Investing LLC grew its holdings in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares during the period. Assetmark Inc. increased its position in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the fourth quarter valued at $40,000. Finally, Quarry LP purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at $79,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GPCR. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.